BSD Medical Corporation Announces Appointment of Ben Beckham as Vice President of North American Sales

SALT LAKE CITY, Feb. 17, 2015 (GLOBE NEWSWIRE) -- BSD Medical Corporation BSDM (Company or BSD), a leading provider of medical systems that utilize heat therapy to treat cancer, today announced the appointment of Ben Beckham as Vice President of North American Sales, effective February 16, 2015. Mr. Beckham is an accomplished and performance-driven life sciences executive with over 20 years of experience in medical sales management and marketing.

Clint Carnell, CEO of BSD Medical, commented, "Ben's signature strengths are the turnarounds of underperforming sales teams, optimization of sales team structure and process, and program creation that drives significantly enhanced end results. As an advisor to the Company since mid-December of the past year, he has already been instrumental in charting our new sales program focused on peer-to-peer influence and top line sales growth through customer adoption. Ben's appointment as head of North American sales is the natural next step in executing our strategic plan for BSD first unveiled last month, and we enthusiastically welcome him to our executive team."

Prior to joining BSD, Mr. Beckham was Vice President of Sales, Americas for Solta Medical, a medical aesthetics company acquired by Valeant Pharmaceuticals International, Inc. in 2014. At Solta, he was responsible for all commercial activity throughout North and South America. Prior to Solta, Mr. Beckham served as Vice President, Sales and Marketing for Lifecore Biomedical, a leader in tissue biologics, dental implants and implantable grafting products. He has also held various sales leadership positions with companies such as Interpore International and GE Medical Systems.

"Clint and his team have already demonstrated significant progress on the Company's turnaround efforts, and it's exciting to play a key role in our new business strategy singularly focused on microwave ablation," said Ben Beckham. "With our new sales program launching this month, I look forward to driving aggressive and highly disciplined sales execution by the team in the months ahead and over the long term."

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy, which is delivered using focused radiofrequency (RF) and microwave energy. BSD's product lines include both hyperthermia and ablation treatment systems. BSD's MicroThermX^® microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company's products have received regulatory approvals and clearances in the United States, Europe and China.

For further information visit BSD Medical's website at BSDMedical.com.

Forward-Looking Statements

Statements contained in this press release that are not historical facts, including statements relating to our intent to divest our hyperthermia business in Spring 2015, focus on microwave ablation to create stockholder value, comply with Nasdaq continued listing requirements, generate capital from a transaction related to our building and pursue other strategic plans are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties, including the risk that for a variety of reasons we may not be able to execute on our strategic plans, and other risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date, except as required by law.